Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors

Overview of attention for article published in Investigational New Drugs, March 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#5 of 1,265)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Dimensions has found 2 publications that cite this research output.

Article in Molecular Carcinogenesis (May 2024)

Article in Expert Opinion on Investigational Drugs (January 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.